Alpha Emitter Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Alpha Emitter Market is segmented by Type of Radionuclide (Astatine (At-211), Radium (Ra-223), Lead (Pb-212)​, Bismuth (Bi-212), Actinium (Ac-225), and Other Type of Radionuclides), Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, and Other Medical Applications), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America).

Market Snapshot

CAGR
Study Period:

2018 - 2026

Base Year:

2020

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

36.7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period (2020 - 2025). Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy and the growing number of patients with cardiac and cancer ailments.

Targeted anticancer or alpha therapy (TAT) is gaining popularity with the increasing prevalence of cancer and cardiovascular diseases. Companies are now increasingly aware of the potential benefits of targeted therapies to treat several chronic ailments. Furthermore, radioimmunotherapy with short-ranged, high-efficiency α-particles is a striking and promising treatment approach. α-particles have an advantage in targeted therapy, due to their exceptionally high cell-killing ability.

However, regulatory requirements pose a hurdle to translational research and clinical investigations. For instance, in the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radio therapeutics, undergo regulatory oversight by the FDA. Similarly, radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways across the world.

Scope of the Report

In therapeutic radiopharmaceuticals, radionuclides with alpha emitters play a significant role in treating cancers. Properties of alpha emitters have led to exert profound differences between this field and other fields of nuclear medicine. Due to their short range and high LET (deposit energy in a unit length of their pathway), alpha particles have remarkably been considered into medical research.

By Type of Radionuclide
Astatine (At-211)
Radium (Ra-223)
Actinium (Ac-225)
Lead (Pb-212)​
Bismuth (Bi-212)
Other Type of Radionuclides
By Medical Application
Prostate Cancer
Bone Metastasis
Ovarian Cancer
Pancreatic Cancer
Endocrine Tumors
Other Medical Applications
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period

  • The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR, by the end of the forecast period.
  • The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women may die from ovarian cancer. Additionally, a recent Phase I clinical trial involving At-211-MX35 F (ab′) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.
  • Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific IP radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies. Moreover, the adoption of targeted alpha therapy, with higher LET and shorter wavelengths, has been promising in the treatment process. This trend is expected to gain traction in the future.
Estimated number of incident cases

To understand key trends, Download Sample Report

North America Dominates the Market and is Expected to do Same During the Forecast Period

  • Currently, North America dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increase in cardiac and neurological chronic diseases, which is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.
  • Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, rising prevalence of the cancer is making it imperative for the healthcare professionals across Canada, to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.
Alpha Emitter Market - Growth Rate by Region

To understand geography trends, Download Sample Report

Competitive Landscape

The alpha emitter market is less competitive and consists of very few major players. Companies, like IBA Radiopharma Solutions, Bayer AG, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Telix Pharmaceuticals Ltd, RadioMedix Inc., and Fusion Pharmaceuticals, hold the substantial market share in the market studied.

A number of developments have been taking place in the market over recent years. For example:

  • November 2017 - Actinium Pharmaceuticals Inc. launched the AWE Program, aka Actinium Warhead Enabling Program, to enable collaborations based on its Actinium-225 Technology Platform. 
  • November 2017 - Alpha Tau Medical Ltd entered a collaboration with IRST Italy to treat its first cancer patient. This is significant progress toward international expansion. This is also expected to enable the availability of Alpha DaRT radiotherapy all across Europe, Asia, and the United States.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy

      2. 4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments

    3. 4.3 Market Restraints

      1. 4.3.1 Short Half-life of Radiopharmaceuticals

      2. 4.3.2 Stringent Regulatory Framework and Reimbursement Issues

      3. 4.3.3 Need for High Capital Investment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Radionuclide

      1. 5.1.1 Astatine (At-211)

      2. 5.1.2 Radium (Ra-223)

      3. 5.1.3 Actinium (Ac-225)

      4. 5.1.4 Lead (Pb-212)​

      5. 5.1.5 Bismuth (Bi-212)

      6. 5.1.6 Other Type of Radionuclides

    2. 5.2 By Medical Application

      1. 5.2.1 Prostate Cancer

      2. 5.2.2 Bone Metastasis

      3. 5.2.3 Ovarian Cancer

      4. 5.2.4 Pancreatic Cancer

      5. 5.2.5 Endocrine Tumors

      6. 5.2.6 Other Medical Applications

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Actinium Pharmaceutical Inc.

      2. 6.1.2 Alpha Tau Medical Ltd

      3. 6.1.3 Bayer AG

      4. 6.1.4 Fusion Pharmaceuticals

      5. 6.1.5 IBA Radiopharma Solutions

      6. 6.1.6 RadioMedix Inc.

      7. 6.1.7 Telix Pharmaceuticals Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Alpha Emitter Market market is studied from 2018 - 2026.

The Alpha Emitter Market is growing at a CAGR of 36.7% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

  • Alpha Tau Medical Ltd
  • IBA Radiopharma Solutions
  • RadioMedix Inc.
  • Bayer AG
  • Actinium Pharmaceuticals Inc.

Are the major companies operating in Alpha Emitter Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!